PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NFPjSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzkb4RnUUN3ME2wMlgzODJ2IN88US=> M37S[nNCVkeHUh?=
UACC-893 NF3nW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwMUm4PFYh|ryP NIj3OXBUSU6JRWK=
A427 NUnFWZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfsTWM2OD13LkeyOVY4KM7:TR?= M3fTNnNCVkeHUh?=
OCUB-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\BZWlEPTB;Nj62OlExOiEQvF2= MVHTRW5ITVJ?
SW684 M4fBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTdwNUKyOlgh|ryP NIDIUZVUSU6JRWK=
SK-LMS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLLTWM2OD17LkCxN|AzKM7:TR?= MXLTRW5ITVJ?
CP50-MEL-B M4PibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XlOmlEPTB;OT6zNFQyQSEQvF2= MWXTRW5ITVJ?
NCI-H1651 NEi2dHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTBTWM2OD1zMD6wNlc3KM7:TR?= NIDSd2VUSU6JRWK=
ABC-1 M4TBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFyLkGwN|ch|ryP MnTaV2FPT0WU
OE19 M33Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfYc2RKSzVyPUGwMlE4OzNizszN MoDEV2FPT0WU
DSH1 NGLuNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNfFlKSzVyPUGwMlg5PzlizszN NIPhWY9USU6JRWK=
SW13 M2DFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyzTWM2OD1zMT65N|E6KM7:TR?= MXrTRW5ITVJ?
MDA-MB-453 NGDufIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nFWWlEPTB;MUKuNVYxOyEQvF2= M13PUXNCVkeHUh?=
647-V NFzIPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVribnZCUUN3ME2xNk4{PTh{IN88US=> M1:0W3NCVkeHUh?=
NCI-H2342 M4LoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES1fHdKSzVyPUGyMlM6QTVizszN M4LpXnNCVkeHUh?=
LB2241-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXYW4FQUUN3ME2xNk42Pzd7IN88US=> MV\TRW5ITVJ?
UACC-257 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVcGtKSzVyPUGzMlQ1PTNizszN MVfTRW5ITVJ?
NCI-H661 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXTO4tKSzVyPUGzMlY1PDlizszN MXjTRW5ITVJ?
FADU MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGwTWM2OD1zMz62PVkzKM7:TR?= MUHTRW5ITVJ?
A2780 NHSwT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XhNWlEPTB;MUOuPFA1OSEQvF2= MVLTRW5ITVJ?
NCI-H1793 NImzRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTYTWM2OD1zND60NFg2KM7:TR?= MkO3V2FPT0WU
TE-8 NWXTXmVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXyNGtKSzVyPUG1MlM1PjVizszN NFzFUYlUSU6JRWK=
HGC-27 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkG2OFQh|ryP NF7IOHpUSU6JRWK=
MMAC-SF NH25emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S1W2lEPTB;MUeuN|czPyEQvF2= NEO5dJZUSU6JRWK=
Calu-6 NIezc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXpfIRpUUN3ME2xPE4yPTF|IN88US=> MVLTRW5ITVJ?
HUTU-80 NIXwbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[3NmlEPTB;MUiuN|k2QSEQvF2= NGjwe5ZUSU6JRWK=
SAS M1nr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn33TWM2OD1zOD62OFU2KM7:TR?= MX7TRW5ITVJ?
IST-MES1 NYrnT3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTtTWM2OD1zOD62OVA5KM7:TR?= MmDEV2FPT0WU
C3A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn2fYI4UUN3ME2xPE44QTF7IN88US=> MYDTRW5ITVJ?
ES3 NXLFPG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKzdW1KSzVyPUG4Mlg{PjRizszN MlS2V2FPT0WU
HSC-2 M3\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\X[2h4UUN3ME2xPU43PTRzIN88US=> M4PQRXNCVkeHUh?=
T47D M1vEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPN[nRmUUN3ME2yNE4yPDh3IN88US=> M4rRXHNCVkeHUh?=
EW-7 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJyLki1PFgh|ryP MU\TRW5ITVJ?
LN-405 NVnU[|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfKdY9KSzVyPUKwMlg6PjVizszN MWjTRW5ITVJ?
U031 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonkTWM2OD1{MT60PFAzKM7:TR?= MX;TRW5ITVJ?
A549 NGXzUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3RWlEPTB;MkGuPFQ6OSEQvF2= MUjTRW5ITVJ?
RMG-I MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPVGlEPTB;MkKuNlY3QCEQvF2= MoC2V2FPT0WU
BT-474 M3X4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Bc2ZKSzVyPUKyMlY2PTFizszN MVPTRW5ITVJ?
NB69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ|LkG1NkDPxE1? M{T1N3NCVkeHUh?=
NB7 M1\CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrOG41UUN3ME2yOE4yQDhizszN NH:5UWNUSU6JRWK=
HCC1569 M1;LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j3dWlEPTB;MkSuOlEzPSEQvF2= MorxV2FPT0WU
MEL-JUSO Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDHTWM2OD1{ND62PVA5KM7:TR?= MV\TRW5ITVJ?
MDA-MB-175-VII NFrlXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ3LkK1NVch|ryP NGXneGxUSU6JRWK=
HCC1419 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJ3Lk[wNFMh|ryP M1rQZnNCVkeHUh?=
Ca9-22 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\6OWJKSzVyPUK1MlY1OzJizszN MYfTRW5ITVJ?
KGN Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nM[WlEPTB;MkWuO|U1PyEQvF2= M2f3[XNCVkeHUh?=
LB373-MEL-D MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\OUphRUUN3ME2yOk4yQTN6IN88US=> NHz3cpFUSU6JRWK=
NCI-H1755 NWDZSFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLLdGFkUUN3ME2yOk45QDRzIN88US=> MlWzV2FPT0WU
D-423MG M1znb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;VXVJzUUN3ME2yO{4xPzF3IN88US=> MVPTRW5ITVJ?
DK-MG NFG1RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L4O2lEPTB;MkiuO|g1PiEQvF2= M1;menNCVkeHUh?=
NCI-H1623 M1nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ6LkizOFIh|ryP NVTFO2w3W0GQR1XS
KU-19-19 NVnPSWhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17aUmlEPTB;MkiuPVk2KM7:TR?= Ml[zV2FPT0WU
C-33-A M{HzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ7LkKxPVgh|ryP NIHNVpZUSU6JRWK=
SCC-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNyLkOzOVQh|ryP NF33ZVRUSU6JRWK=
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PUcGlEPTB;M{CuOVk6PCEQvF2= NHXV[YpUSU6JRWK=
LNCaP-Clone-FGC NF\1eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUUGlEPTB;M{GuOFkzOSEQvF2= NGS1N2xUSU6JRWK=
CAPAN-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNzLkWyPFYh|ryP M2fZfHNCVkeHUh?=
GI-ME-N M3rZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D2TGlEPTB;M{GuOVM2OyEQvF2= NYnIVnpjW0GQR1XS
RERF-LC-MS NUfYTnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f2S2lEPTB;M{KuOlc1PyEQvF2= MkTYV2FPT0WU
KLE NXHPVoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCeGlEPTB;M{OuOFM{PCEQvF2= MYjTRW5ITVJ?
KNS-81-FD Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rpNmlEPTB;M{OuOVAxQCEQvF2= NGGwdlFUSU6JRWK=
DOK M3u0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm3Z5ZJUUN3ME2zOE43PjF{IN88US=> MV;TRW5ITVJ?
ACHN M3jvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPSTY9[UUN3ME2zOU4yPTh6IN88US=> MWfTRW5ITVJ?
KYSE-520 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPNUJNKSzVyPUO1MlI{PjFizszN MV7TRW5ITVJ?
SBC-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i4R2lEPTB;M{WuOVEyPiEQvF2= MnfZV2FPT0WU
NCI-H28 NFzSbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH23dXFKSzVyPUO1MlY3QTVizszN M3\od3NCVkeHUh?=
ES7 NIjSe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPoTWM2OD1|Nj6yNlQ6KM7:TR?= M1TrOXNCVkeHUh?=
A172 M1v6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSzPXF4UUN3ME2zOk41OTh5IN88US=> NY\ofmtIW0GQR1XS
UM-UC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN5Lki3OFYh|ryP NYLMb4pLW0GQR1XS
LXF-289 NGDiUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN6LkCwOFch|ryP MknwV2FPT0WU
KP-4 M2rBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN6LkS3N|kh|ryP MoTLV2FPT0WU
TE-1 NVTlSHdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M134RmlEPTB;M{muOlU5QSEQvF2= MnrQV2FPT0WU
G-402 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYdmlEPTB;NECuNFYyKM7:TR?= M3vRVHNCVkeHUh?=
786-0 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7KVFJKSzVyPUSwMlkxQTZizszN MVHTRW5ITVJ?
K5 NG\rdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\pZ|hKSzVyPUSxMlM3QDZizszN M37x[HNCVkeHUh?=
SK-N-DZ MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHwNoVKSzVyPUSxMlM5OjNizszN M3fheXNCVkeHUh?=
OVCAR-4 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0fVJ{UUN3ME20NU44PTZ6IN88US=> MUHTRW5ITVJ?
T84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR{LkGyOlMh|ryP NFXGWGVUSU6JRWK=
GCIY NVnaW4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fVdWlEPTB;NEOuNFgxOyEQvF2= M3q4RnNCVkeHUh?=
BB49-HNC NXTWZVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXUSVZKSzVyPUSzMlM{PDhizszN MlvYV2FPT0WU
SNU-C2B MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTR|Lk[0N|Yh|ryP MofHV2FPT0WU
TE-6 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzpTWM2OD12Mz64PFk1KM7:TR?= M4DRTXNCVkeHUh?=
23132-87 M3zsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR2LkK5O|gh|ryP M1v1XXNCVkeHUh?=
DMS-53 NYXlb3NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonETWM2OD12ND6zN|g1KM7:TR?= MkX4V2FPT0WU
ONS-76 NETiWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rpfWlEPTB;NESuO|Y3OSEQvF2= MWTTRW5ITVJ?
DMS-273 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR2Lkm0N{DPxE1? NUHpTXV{W0GQR1XS
COLO-824 M4TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1UItKSzVyPUS1Mlg4PzVizszN NXHHSW1uW0GQR1XS
DMS-114 NF;COo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6NWlEPTB;NEWuPFkzPyEQvF2= MX\TRW5ITVJ?
YKG-1 NHLudXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLoTWM2OD12Nj6wN|U2KM7:TR?= MonWV2FPT0WU
RH-18 NHOyPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDSTWM2OD12Nj6zO|M{KM7:TR?= M2nIdnNCVkeHUh?=
NCI-H1355 NVjKUZhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LlXmlEPTB;NE[uOlE5KM7:TR?= MmW5V2FPT0WU
NCI-H2170 NX;F[lhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNeWlEPTB;NEeuO|U5PCEQvF2= NWiyWldlW0GQR1XS
OC-314 M4W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;lPXNKSzVyPUS3Mlg1PzhizszN NUHvUVRFW0GQR1XS
NCI-H2030 NVzEXJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmxO|hKSzVyPUS3Mlg6ODZizszN M2HRRnNCVkeHUh?=
22RV1 NWfBO4Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133ZWlEPTB;NEeuPVAyPSEQvF2= M2jieXNCVkeHUh?=
G-401 NGC5TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR6LkS0NVUh|ryP NUDLboRDW0GQR1XS
YAPC NGDMSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzjellKSzVyPUS5MlgxPzNizszN NVXlOY94W0GQR1XS
SW1573 NF34OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDCTWM2OD13MD6yOFM2KM7:TR?= NGS0fnJUSU6JRWK=
COLO-792 M2rtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqxbpdKSzVyPUWwMlYzOzdizszN MmfCV2FPT0WU
KNS-62 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rheWlEPTB;NUCuO|UxQCEQvF2= MkfqV2FPT0WU
NB5 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TufGlEPTB;NUGuOFUxQSEQvF2= NX\qd5V{W0GQR1XS
CP66-MEL NFjBNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTBUYxRUUN3ME21NU43PDB6IN88US=> NHO3S3BUSU6JRWK=
CaR-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi2Nlg2UUN3ME21Nk4xPjB4IN88US=> NGPQcFNUSU6JRWK=
CAL-54 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjhSnIyUUN3ME21Nk4yOTB{IN88US=> M4XadXNCVkeHUh?=
8305C Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\vTWM2OD13Mj6zNVUh|ryP M2jmcXNCVkeHUh?=
Calu-3 NUT6OHNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4TWM2OD13Mj6zO|M{KM7:TR?= M3f4O3NCVkeHUh?=
AU565 M{f1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u1eWlEPTB;NUKuOVUxQSEQvF2= MVzTRW5ITVJ?
CW-2 MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTV{Lki2OVQh|ryP NEfFe2xUSU6JRWK=
BEN M3nsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHyTWM2OD13Mz63PFYzKM7:TR?= NYO5VWEyW0GQR1XS
NCI-H1975 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTV|Lki5OlYh|ryP M1fCXHNCVkeHUh?=
HCT-116 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXYNJBRUUN3ME21OE4xOzJ5IN88US=> M3XnUXNCVkeHUh?=
SH-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ITWM2OD13ND6xN|gh|ryP MV3TRW5ITVJ?
NCI-H1693 M3TnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTV2LkKxNFMh|ryP MVXTRW5ITVJ?
BPH-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX72OJhnUUN3ME21OU4zQDl{IN88US=> M3eyPXNCVkeHUh?=
CAMA-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr6[HJKSzVyPUW1MlgyOTZizszN M3nwXHNCVkeHUh?=
A388 NF[zNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\UTWM2OD13Nj6wPVg2KM7:TR?= MoP2V2FPT0WU
C2BBe1 NYHpN4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTV4LkK2N|Qh|ryP NIPMWJJUSU6JRWK=
GAMG NF22NZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTV4LkW5OVUh|ryP MUPTRW5ITVJ?
MKN28 NHfsZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD13Nj64NFE{KM7:TR?= MYHTRW5ITVJ?
VA-ES-BJ NEPYOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO0T3FKSzVyPUW2Mlg4PDVizszN MVrTRW5ITVJ?
HuCCT1 M3zMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LFNWlEPTB;NUeuNFQ6OiEQvF2= NHHkWldUSU6JRWK=
BFTC-905 NHe2cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTV5LkK4PVgh|ryP MYPTRW5ITVJ?
LS-123 NH;iZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LKbWlEPTB;NUeuOVY3QCEQvF2= MVjTRW5ITVJ?
LB996-RCC M3P2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTV6LkCyPFch|ryP MYfTRW5ITVJ?
NCI-H1048 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjzTWM2OD13OD6yNVg5KM7:TR?= MYrTRW5ITVJ?
COR-L105 NETZeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17aZWlEPTB;NUiuO|M{PyEQvF2= NUfGV2tmW0GQR1XS
OVCAR-8 M1fkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD13OT6xO|E3KM7:TR?= M{PkdXNCVkeHUh?=
SK-N-FI M4fOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\vTWM2OD13OT6zNlA4KM7:TR?= NVS0Xmp[W0GQR1XS
MES-SA MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\sTWM2OD13OT60OVA6KM7:TR?= MmfXV2FPT0WU
SCC-9 NYHEOGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTV7LkS3OVMh|ryP MmX4V2FPT0WU
EFO-27 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqyO5VRUUN3ME21PU46PDNizszN MorYV2FPT0WU
GT3TKB NXHHW5hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O5SmlEPTB;NkCuOlA1QCEQvF2= MkTsV2FPT0WU
HCC38 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHOT3FyUUN3ME22NU41Ozd7IN88US=> MnrHV2FPT0WU
MLMA MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XQO2lEPTB;NkGuOlE3OyEQvF2= NVniOIw1W0GQR1XS
D-566MG NV3XWphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJUIZPUUN3ME22N{42OjJ2IN88US=> NYX1[nlJW0GQR1XS
SF295 NFj2fopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD14Mz62OlU2KM7:TR?= NHXR[YtUSU6JRWK=
ES4 NIXpWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZ2LkS3NVkh|ryP M1rhd3NCVkeHUh?=
CAKI-1 NFLWNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ezN2lEPTB;NkSuOVczOSEQvF2= MXHTRW5ITVJ?
OAW-28 NGnK[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDX[JlKSzVyPU[0Mlk3PDdizszN MkX5V2FPT0WU
NCI-H460 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZ3LkC4PVch|ryP NWi3TIVlW0GQR1XS
JAR NUDpelBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLJeG9KSzVyPU[1MlU2OTZizszN NYK4OWcxW0GQR1XS
SNU-449 NIjqbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfa[2FJUUN3ME22OU44PjF4IN88US=> M3ntTnNCVkeHUh?=
D-392MG NV\1SGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCx[VVwUUN3ME22OU46PDN2IN88US=> M1HF[3NCVkeHUh?=
EW-22 M4C2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf5TJFXUUN3ME22Ok4{QTVizszN MmHUV2FPT0WU
GCT M33Sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZ5LkC0OFMh|ryP M{O4TnNCVkeHUh?=
NOS-1 NV:3R5ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTZ5Lk[4Olch|ryP M4PZO3NCVkeHUh?=
RH-1 M2fqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn5eZVKSzVyPU[4MlU2PTlizszN MV3TRW5ITVJ?
HuH-7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZ7LkGwNFIh|ryP NVn0OJZJW0GQR1XS
NUGC-3 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fpbGlEPTB;N{CuPVY1PCEQvF2= MXfTRW5ITVJ?
IST-SL1 NX3vfpdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnzVWVKSzVyPUexMlI{OjRizszN NEHEUpNUSU6JRWK=
SHP-77 NVzMUmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTd{LkGxPUDPxE1? MlTHV2FPT0WU
SW1116 NYHyflZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTd{LkG0NFch|ryP Mn7BV2FPT0WU
LK-2 NWL5dZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\yTWM2OD15Mj64OlEzKM7:TR?= MorCV2FPT0WU
U-2-OS MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTpfWZKSzVyPUezMlE5OjhizszN M{HZWXNCVkeHUh?=
KYSE-150 M2fwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\2TWlEPTB;N{OuOlEyQCEQvF2= NV70XVBIW0GQR1XS
U251 NFKxO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Bb2JlUUN3ME23N{45OTZ6IN88US=> M1jDcnNCVkeHUh?=
HT-1080 NV7EW3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfK[FRRUUN3ME23OE4zPTd2IN88US=> NUO3N2tsW0GQR1XS
NCI-H1437 NGf6[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTd2Lk[zNlYh|ryP MVHTRW5ITVJ?
HPAF-II NWqwfWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTd2Lk[0NVUh|ryP MVTTRW5ITVJ?
Becker Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrhXHNMUUN3ME23OU4yOTB3IN88US=> M2TQWXNCVkeHUh?=
PANC-10-05 M3vxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS2TIlKSzVyPUe1MlI5PjVizszN MkjEV2FPT0WU
TYK-nu NF3XWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLCTWM2OD15NT6zNVAzKM7:TR?= MVjTRW5ITVJ?
SKG-IIIa NHriPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fWV2lEPTB;N{WuN|M1OSEQvF2= MnXZV2FPT0WU
NCI-H1993 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml20TWM2OD15NT63N|k4KM7:TR?= MWDTRW5ITVJ?
S-117 M3fCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTd3Lke1OUDPxE1? NW[4cVc3W0GQR1XS
HuO9 M1e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHSZ4hKSzVyPUe2MlAxPDhizszN M2LwV3NCVkeHUh?=
CAL-51 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITNOHpKSzVyPUe2MlExODZizszN M3vkVHNCVkeHUh?=
BT-20 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3[GlEPTB;N{[uNlE3QCEQvF2= MYHTRW5ITVJ?
LB831-BLC NIjLNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XBXmlEPTB;N{[uN|IyPyEQvF2= NUX6fmZXW0GQR1XS
LB1047-RCC MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfQTWM2OD15Nj63OlE6KM7:TR?= NWr1N2FsW0GQR1XS
ES8 M{jTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxSmlEPTB;N{iuNFA4OyEQvF2= MoLvV2FPT0WU
UMC-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L1cGlEPTB;N{iuNFg5PCEQvF2= M1;tU3NCVkeHUh?=
NCI-H226 NVfmVHViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1WWlEPTB;N{iuNVMyPSEQvF2= MnvRV2FPT0WU
IGROV-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTd6LkW1OUDPxE1? MWfTRW5ITVJ?
BHY MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC2RW9MUUN3ME23PU42QTZizszN NYDLeWRrW0GQR1XS
MKN45 M1nhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLuTWM2OD16MD6zNVc1KM7:TR?= Mn6wV2FPT0WU
IA-LM NHexcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;0VmlEPTB;OECuN|UyOSEQvF2= MUTTRW5ITVJ?
WM-115 NIP6UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRThzLkSxNVQh|ryP MmjRV2FPT0WU
VMRC-RCZ MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jvc2lEPTB;OEGuOFQzPSEQvF2= NHXIOplUSU6JRWK=
NCI-H2291 NGHPeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\0[nZ6UUN3ME24NU43QDR{IN88US=> NF[zSYpUSU6JRWK=
MCF7 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LXbmlEPTB;OEOuNlg6PyEQvF2= MYrTRW5ITVJ?
639-V NVfRR|I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTrS2dYUUN3ME24OE43OTJ7IN88US=> MVHTRW5ITVJ?
RT4 M2exOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T2eWlEPTB;OEWuNlQxOyEQvF2= M{C2O3NCVkeHUh?=
NCI-H2405 NUiwZm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33KbGlEPTB;OEWuNlk6PyEQvF2= M3SwOnNCVkeHUh?=
CAL-33 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr6d2pKSzVyPUi1MlY{OTVizszN M3fHenNCVkeHUh?=
BT-549 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLiTWM2OD16NT65N|gzKM7:TR?= M2HSc3NCVkeHUh?=
HT-1197 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnwbVBKSzVyPUi4MlExPzdizszN MUDTRW5ITVJ?
G-361 NXz2RmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH6VHNKSzVyPUi4MlE1PzRizszN MoKzV2FPT0WU
LS-411N M1Ht[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrHPIZKSzVyPUi5MlM{QDhizszN M{\nR3NCVkeHUh?=
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr6bFA5UUN3ME24PU42QTl{IN88US=> M4DJRXNCVkeHUh?=
DJM-1 NVXxS45xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBSWhKSzVyPUi5Mlg5PDVizszN NEfYb5VUSU6JRWK=
CAL-12T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUXGlEPTB;OUCuO|g6PSEQvF2= MmPpV2FPT0WU
MKN7 M4n5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfPcI5KSzVyPUmxMlM2PTFizszN NEjRTZhUSU6JRWK=
HuP-T3 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nmeGlEPTB;OU[uNVAxPCEQvF2= M2HyfnNCVkeHUh?=
SK-MG-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fWV2lEPTB;OU[uNVM1QCEQvF2= Ml3mV2FPT0WU
NCI-H2347 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPkTZRMUUN3ME25PE4yODR{IN88US=> NULrOYRxW0GQR1XS
SW872 NF3PRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFyMD60OVYh|ryP MXjTRW5ITVJ?
COLO-829 NWXINohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDWnVKSzVyPUGwNE42PTNizszN NGG0UnhUSU6JRWK=
MC-IXC M3T2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1NVBNUUN3ME2xNFAvPjF3IN88US=> NH33XVRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID